Advances in Therapy

, Volume 23, Issue 3, pp 456–468 | Cite as

Evaluation of thep53 tumor suppressor gene mutation in normal rat salivary gland tissue after radioiodine application: An experimental study

  • Bulent Turgut
  • Ozturk Ozdemir
  • Taner Erselcan
Article

Abstract

In this experimental study, investigators exploredp53 tumor suppressor gene mutation induced by low and high doses of iodine-131 sodium iodide (I-131) in salivary gland tissue in rats. Group 1 consisted of 10 rats; low and high I-131 doses were applied at a 1-wk interval. First, low doses of I-131 were injected. (The net injected dose was 47.5±9.2 μCi.) After 1 wk, high doses of I-131 were also injected. (The net injected dose was 1007.2±53 μCi.) Group 2 consisted of 5 rats, and only a low I-131 dose was applied. (The net injected dose was 52.7±5.5 μCi.) The Control Group consisted of 5 rats that did not receive I-131. Thyroidal I-131 uptakes were calculated for Groups 1 and 2 with the use of a gamma camera after 24 h of injections. Immediately after uptake was calculated, salivary glands were resected in all groups and DNA was extracted for genotyping. Genomic DNA of thep53 gene exon 5 was examined by polymerase chain reaction single-strand conformational polymorphism. In Group 1, thyroidal I-131 uptakes were calculated as 12.45%±4.14% and 9.66%±6.73% after low-dose and high-dose I-131 applications, respectively. In Group 2, thyroidal I-131 uptake was calculated as 13.12%±3.04%. In Group 1,p53 gene abnormality was seen in the salivary gland of only 1 of the rats. Double and single-strand gene profiles showed that both alleles of this rat have a mutated single-strand conformational polymorphism profile of point mutation in thep53 gene exon 5. This rat received the highest low dose and the second highest total dose of I-131; its thyroidal uptakes were the second highest. In the other rats in Group 1, and in Group 2 and the Control Group,p53 gene abnormalities were not observed. In Groups 1 and 2, a significant relationship could not be discerned between thyroidal uptake of I-131 andp53 gene mutation in the salivary gland. No significant relationship was observed between thyroidal uptake alterations andp53 gene mutations in salivary glands in Group 1. A point mutation in thep53 gene exon 5 that was seen in only 1 of the rats in Group 1 seems related to the high-dose application of I-131, although coincidental occurrences could not be excluded. We believe that this topic is open to additional in vivo studies.

Keywords

iodine-131 salivary gland rat p53 gene gene mutation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vatulina GG, Tuzhilkova TN, Goloshchapova ZhA. Postradiation changes in the thyroid gland and skeletal muscle after exposure to iodine-131.Radiobiologiia. 1986;26:499–505.PubMedGoogle Scholar
  2. 2.
    Guiraud-Vitaux F, Feldmann G, Vadrod N, et al. Early ultrastructural injuries in the thyroid of the normal rat radioinduced by diagnostic and/or therapeutic amounts of iodine 131.Cell Mol Biol (Noisy-le-grand). 2001;47:495–502.Google Scholar
  3. 3.
    Swiatecka J, Dzieciol J, Anchim T, Dabrowska M, Pietruczuk M, Wolczynski S. Influence of estrogen, antiestrogen and UV-light on the balance between proliferation and apoptosis in MCF-7 breast adenocarcinoma cell culture.Neoplasma. 2000;47:15–24.PubMedGoogle Scholar
  4. 4.
    Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.Clin Nucl Med. 2002;27:767–771.PubMedCrossRefGoogle Scholar
  5. 5.
    Kita T, Yokoyama K, Higuchi T, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma.Ann Nucl Med. 2004;18:345–349.PubMedCrossRefGoogle Scholar
  6. 6.
    Zheng R, Wang LE, Bondy ML, Wei Q, Sturgis EM. Gamma radiation sensitivity and risk of malignant and benign salivary gland tumors: a pilot case-control analysis.Cancer. 2004;100: 561–567.PubMedCrossRefGoogle Scholar
  7. 7.
    Zheng R, Dahlstrom KR, Wei Q, Sturgis EM. Gamma radiation-induced apoptosis, G2 delay, and the risks of salivary and thyroid carcinomas—a preliminary report.Head Neck. 2004;26: 612–618.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez-Cuevas S, Ocampo LB. A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma.Eur J Surg Oncol. 1995; 21:692.PubMedCrossRefGoogle Scholar
  9. 9.
    Henze M, Pittel JP, Elser H. Mucoepidermoid carcinoma of the submandibular gland after high-dose radioiodine therapy: a case report and review of the literature.Nuclearmedizin. 1998;37: 45–49.Google Scholar
  10. 10.
    Gamble SC, Cook MC, Riches AC, Herceg Z, Bryant PE, Arrand JE.p53 mutations in tumors derived from irradiated human thyroid epithelial cells.Mutat Res. 1999;425:231–238.PubMedGoogle Scholar
  11. 11.
    Soussi T, Dehouche K, Beroud C.p53 website and analysis ofp53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis.Hum Mutat. 2000;15:105–113.PubMedCrossRefGoogle Scholar
  12. 12.
    Lane DP. Cancer.p53, guardian of the genome.Nature. 1992;358:15–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Vahakangas K.TP53 mutations in exposed workers.Hum Mutat. 2003;21:229–239.CrossRefGoogle Scholar
  14. 14.
    Shingu K, Kobayashi S, Yokoyama S, et al. The likely transformation of papillary thyroid carcinoma into anaplastic carcinoma during postoperative radioactive iodine-131 therapy: report of a case.Surg Today. 2000;30:910–913.PubMedCrossRefGoogle Scholar
  15. 15.
    Takahashi S, Thuy DT, Sato H, Kubota Y, Sun XZ, Chandrasekharan NV. Effects of the restriction of food and water intake on the distribution and retention of radioiodine in mice.J Radiat Res. 2000;41:313–320.PubMedCrossRefGoogle Scholar
  16. 16.
    Ozdemir O, Bulut HE, Korkmaz M, Onarlioglu B, Colak A. Increased cell proliferation and R.Msp1 fragmentation induced by 5-aza-2′-deoxycytidine in rat testes related to the gene imprinting mechanism.Exp Toxicol Pathol. 2000;52:317–322.PubMedGoogle Scholar
  17. 17.
    Ozdemir O, Bardakcy F, Egilmez H, Egilmez R. Subcutaneous undifferentiated sarcoma induced by N′-ethyl-N′-nitrosourea in rat: radiology, histopathology and mutagenesis.Exp Toxicol Pathol. 2003;55:295–300.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandler MP, Coleman RE, Patton JA, Wackers FJT, Gottschalk A, eds.Basic Physics of Nuclear Medicine, Section I: Physics and Instrumentation. Diagnostic Nuclear Medicine. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:16.Google Scholar
  19. 19.
    Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer.Semin Nucl Med. 1997;27:152–164.PubMedCrossRefGoogle Scholar
  20. 20.
    Reilly CP, Symons RG, Wellby ML. A rat model of the 131I-induced changes in thyroid function.J Endocrinol Invest. 1986;9:367–370.Google Scholar
  21. 21.
    Hanauer G. Estimate of the dosage for radioiodine ablation of the thyroid gland in male Wistar rats.Zentralbl Veterinarmed A. 1990;37:747–751.PubMedGoogle Scholar
  22. 22.
    Erselcan T, Sungu S, Ozdemir S, Turgut B, Dogan D, Ozdemir O. I-131 treatment and chromosomal damage: in-vivo dose-effect relationship.Eur J Nucl Med Mol Imaging. 2004;31:676–684.PubMedCrossRefGoogle Scholar
  23. 23.
    Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations ofp53 and ras genes in radon-associated lung cancer from uranium miners.Lancet. 1992;339:576–580.PubMedCrossRefGoogle Scholar
  24. 24.
    Soussi T, Beroud C. AssessingTP53 status in human tumours to evaluate clinical outcome.Nat Rev Cancer. 2001;1:233–240.PubMedCrossRefGoogle Scholar
  25. 25.
    Liu S, Bishop WR, Dasmahapatra B, Wang Y. Pharmacogenomics of thep53 tumor suppressor and its role in cancer chemoresistance.Drug Develop Res. 2004;62:254–272.CrossRefGoogle Scholar
  26. 26.
    Geoffrey M. Tumor suppressor genes (Chapter 15). In: Cooper, ed.Cancer. The Cell: A Molecular Approach. Washington DC: ASM Press; 1997:625.Google Scholar
  27. 27.
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in thep53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.Cancer Res. 1994;54:4855–4878.PubMedGoogle Scholar
  28. 28.
    Caron de Fromentel C, Soussi T.TP53 tumor suppressor gene: a model for investigating human mutagenesis.Genes Chrom Cancer. 1992;4:1–15.CrossRefGoogle Scholar
  29. 29.
    Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in thep53 gene occur in diverse human tumour types.Nature. 1989;342:705–708.PubMedCrossRefGoogle Scholar
  30. 30.
    Miller CW, Simon K, Aslo A, et al.p53 mutations in human lung tumours.Cancer Res. 1992; 52:1695–1698.PubMedGoogle Scholar
  31. 31.
    Lu X, Lane DP. Differential induction of transcriptionally activep53 following UV or ionizing radiation: defects in chromosome instability syndromes.Cell. 1993;75:765–778.PubMedCrossRefGoogle Scholar
  32. 32.
    Colucci S, Mothersill C, Harney J, Gamble SC, Seymour C, Arrand JE. Induction of multiple PCR-SSCPE mobility shifts inp53 exons in cultures of normal human urothelium exposed to low-dose gamma-radiation.Int J Radiat Biol. 1997;72:21–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage.Cancer Res. 1991;51:6304–6311.PubMedGoogle Scholar
  34. 34.
    Smith ML, Chen IT, Zhan QM, et al. Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen.Science. 1994;266:1376–1380.PubMedCrossRefGoogle Scholar
  35. 35.
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.Cell. 1993;74:957–967.PubMedCrossRefGoogle Scholar
  36. 36.
    Potencz E, Cornianu M, Muntean C, Sotiriadis S. The expression of p53 protein in salivary gland carcinomas.Rom J Morphol Embryol. 1998;44:109–115.PubMedGoogle Scholar
  37. 37.
    Ko LJ, Prives C.p53: puzzle and paradigm.Genes Dev. 1996;10:1054–1072.PubMedCrossRefGoogle Scholar
  38. 38.
    Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation withp53 gene alterations.Hum Pathol. 1999;30:1221–1225.PubMedCrossRefGoogle Scholar
  39. 39.
    Blons H, Laurent-Puig P.TP53 and head and neck neoplasms.Hum Mutat. 2003;21:252–257.PubMedCrossRefGoogle Scholar
  40. 40.
    Boyle JO, Hakim J, Koch W, et al. The incidence ofp53 mutations increases with progression of head and neck cancer.Cancer Res. 1993;53:4477–4480.PubMedGoogle Scholar
  41. 41.
    Weber A, Langhanki L, Schutz A, et al. Expression profiles ofp53, p63 andp73 in benign salivary gland tumors.Virchows Arch. 2002;441:428–436.PubMedCrossRefGoogle Scholar
  42. 42.
    Kojima M, Nakamura S, Ichimura K, Shimizu K, Itoh H, Masawa N. Follicular lymphoma of the salivary gland: a clinicopathological and molecular study of six cases.Int J Surg Pathol. 2001;9:287–293.PubMedCrossRefGoogle Scholar
  43. 43.
    Nagao T, Sugano I, Ishida Y, et al. Hybrid carcinomas of the salivary glands: report of nine cases with a clinicopathologic, immunohistochemical, andp53 gene alteration analysis.Mod Pathol. 2002;15:724–733.PubMedCrossRefGoogle Scholar
  44. 44.
    Daa T, Kashima K, Gamachi A, Nakayama I, Yokoyama S. Epithelial-myoepithelial carcinoma harboringp53 mutation.APMIS. 2001;109:316–320.PubMedCrossRefGoogle Scholar
  45. 45.
    Nordkvist A, Riojer E, Bang G, et al. Expression and mutation patterns ofp53 in benign and malignant salivary gland tumors.Int J Oncol. 2000;16:477–483.PubMedGoogle Scholar
  46. 46.
    Brennan JA, Mao L, Hruban LH, et al. Molecular assessment of histopathological staining in squamous cell carcinoma of the head and neck.N Engl J Med. 1995;332:429–435.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2006

Authors and Affiliations

  • Bulent Turgut
    • 1
  • Ozturk Ozdemir
    • 2
  • Taner Erselcan
    • 1
  1. 1.Department of Nuclear MedicineCumhuriyet University School of MedicineSivasTurkey
  2. 2.Department of Medical GeneticsCumhuriyet University School of MedicineSivasTurkey

Personalised recommendations